Devonyu/iStock via Getty Images
Johnson & Johnson (NYSE:JNJ) announced on Saturday the initial results from a group of patients who were part of its SunRISe-1 Phase 2b trial for TAR-200, an intravesical releasing system of chemotherapy gemcitabine targeted at certain forms of bladder cancer.